Article
Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer.
BMC cancer - 4 Dec 2012
Suzumura Tomohiro, Kimura Tatsuo, Kudoh Shinzoh, Umekawa Kanako, Nagata Misato, Matsuura Kuniomi, Tanaka Hidenori, Mitsuoka Shigeki, Yoshimura Naruo, Kira Yukimi, Nakai Toshiyuki, Hirata Kazuto
Abstract excerpt
BACKGROUND: Rash, liver dysfunction, and diarrhea are known major adverse events associated with erlotinib and gefitinib. However, clinical trials with gefitinib have reported different proportions of adverse events compared to trials with erlotinib. In an in vitro study, cytochrome P450 (CYP) 2D6 was shown to be involved in the metabolism of gefitinib but not erlotinib. It has been hypothesized that CYP2D6...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.